The filing is a routine Form 144 by a director exercising and selling option shares. The small size relative to market cap and total shares outstanding suggests no material insider signal. Monitor for any subsequent Form 4 filings to confirm execution.
REGN drugs
REGN drug pipeline →- ● Otarmeni 3/10 Approved (accelerated approval) · BLA filing 2026
- ▲ Cemdisiran 6/10 Filed/PDUFA (Phase 3 NIMBLE complete; NDA under FDA Priority Review)
- ▲ Dupixent 4/10 Approved (marketed since 2017; additional Phase 3 trials ongoing for label expansion)
- ● Evkeeza 4/10 Approved
- ● EYLEA HD 4/10 Approved
- 12 more · All REGN drugs, catalysts & trials →
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+5- T+0 · Nov 2 $961.26entry
- T+1 · 14d ago +1.26%α +0.96% · $973.36
- T+5 · 8d ago −4.30%α −4.37% · $919.96
- T+10 · todayOpen
- T+20 · in 14d Pending
- T+60 · in 2mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Director Michael S. Brown filed a Form 144 notice of intent to sell 1,929 shares of Regeneron common stock, with an approximate market value of $1.58 million based on the filing date. The shares were acquired through stock option exercises, and the sale is planned for execution on October 30, 2026.
Key Facts
- Reporting person: Michael S. Brown, a Director of Regeneron Pharmaceuticals, Inc.
- Proposed sale of 1,929 shares of common stock.
- Estimated aggregate market value: $1,579,407.33.
- Shares acquired via exercise of stock options on October 30, 2026.
- Broker: Morgan Stanley Smith Barney LLC Executive Financial Services.
- Sale intended to be executed on October 30, 2026.
- Total shares outstanding (approximate): 103,447,859.
- Proposed sale represents approximately 0.002% of shares outstanding.
Financial Impact
Proposed sale of 1,929 shares valued at approximately $1.58 million, representing about 0.002% of outstanding shares.
Risk Factors
- Form 144 is an intent to sell; the sale may not be executed.
- Insider selling, even small, can be perceived negatively by some market participants.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 144 Filing (Primary) | 0001950047-26-010507 |
| Document: 0001950047-26-010507-index.html | 0001950047-26-010507 |
| Document: 0001950047-26-010507.txt | 0001950047-26-010507 |
Track record
53 reports on REGN
11 of 17 bullish or bearish reports moved the stock their way by T+20. Best: +31.76% at T+20 after the Oct 6, 2026 report. 17 of 21 went positive at some point.
Filters
- Nov 16, 2026today 144 Neutral 2/10 Entry $951.23 Now $952.40 +0.12% settles Dec 16
- Nov 16, 2026today 144 Neutral 2/10 Entry $948.00 Now $952.40 +0.46% settles Dec 16
- Nov 12, 20264d ago Press Release Bullish 5/10 Entry $955.47 Now $952.40 −0.32% settles Dec 14
- Nov 5, 202611d ago Insider Cluster Neutral 2/10 Entry $904.35 Now $952.40 +5.31% settles Dec 7
- Nov 5, 202611d ago Insider Cluster Neutral 3/10 Entry $904.35 Now $952.40 +5.31% settles Dec 7
- Nov 4, 202612d ago 144 Neutral 1/10 Entry $902.90 Now $952.40 +5.48% settles Dec 4
- Nov 4, 202612d ago 144 Neutral 2/10 Entry $902.90 Now $952.40 +5.48% settles Dec 4
- Nov 3, 202613d ago Insider Cluster Neutral 2/10 Entry $930.67 Now $952.40 +2.33% settles Dec 3
- Nov 3, 202613d ago 144 Neutral 2/10 Entry $930.67 Now $952.40 +2.33% settles Dec 3
- Nov 3, 202613d ago Insider Cluster Neutral 2/10 Entry $930.67 Now $952.40 +2.33% settles Dec 3
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers